Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 8/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 3/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.36 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412856 | 0.80 | CYP2C9 (0.65) | CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL16253672 | 0.79 | BRAF (0.42) | CYP2C9CYP3A4CYP2C19BRAFKIT | |
| SCHEMBL7875034 | 0.74 | CYP2C9 (0.80) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL298756 | 0.74 | CYP2C9 (0.61) | CYP2C9CYP3A4CYP2C19CYP2D6PTGS1 | |
| SCHEMBL3010599 | 0.74 | BRAF (0.41) | BRAFKITALOX5APFEN1ACLY | |
| SCHEMBL26812006 | 0.74 | BRAF (0.39) | BRAFKITPTGS1PTGS2CKS1B | |
| SCHEMBL3008478 | 0.74 | BRAF (0.43) | BRAFKITPTGS1PTGS2CKS1B | |
| SCHEMBL413622 | 0.73 | CYP2C9 (0.60) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL856150 | 0.73 | CYP2C9 (0.60) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL25450126 | 0.73 | BRAF (0.42) | BRAFMRGPRX1ALOX5APFEN1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C9 2176/4885CYP3A4 3611/4885CYP2C19 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.